FTC Requests Extra Details on MiMedx Group Merger With Sanara, Pausing Review Period
MiMedx Group, Inc. (MDXG) received a Second Request from the Federal Trade Commission on Oct. 15, 2026, requesting additional documentation and information regarding its pending merger with Sanara. The request pauses and extends the required Hart-Scott-Rodino waiting period for antitrust review. Shares of MiMedx Group traded at 4.68 USD following the disclosure, down 0.43% for the day.
The regulatory delay prolongs the approval process for the transaction. Under federal antitrust regulations, the waiting period will remain paused until 30 days after the company substantially complies with the demand for documents, unless officials terminate the review earlier. Completing the deal remains subject to successfully clearing this waiting period and satisfying or waiving other closing conditions.
MiMedx Group stated that it is continuing to cooperate fully with federal regulators. Investors will be monitoring how quickly the company submits the required material to restart the regulatory clock, as well as any future updates regarding closing timing and expected transaction outcomes.
Key points
- The Federal Trade Commission issued a Second Request on Oct. 15, 2026, seeking additional documentation regarding the proposed merger with Sanara.
- The request pauses the Hart-Scott-Rodino waiting period until 30 days after substantial compliance or early regulatory termination.
- Finalizing the merger remains subject to successfully clearing the regulatory waiting period and satisfying remaining closing conditions.
- MiMedx Group is cooperating with federal officials while noting ongoing uncertainties around transaction timing and prospective benefits.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why was the MiMedx Group and Sanara merger delayed?
The Federal Trade Commission issued a Second Request for additional documents and information, extending the required regulatory waiting period.
How long is the regulatory waiting period extended for MiMedx Group?
The waiting period is paused until 30 days after MiMedx Group substantially complies with the FTC request, unless terminated earlier by regulators.
What must happen before the merger between MiMedx Group and Sanara can close?
The merger requires the end of the Hart-Scott-Rodino waiting period and the satisfaction or waiver of remaining closing conditions.